BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

664 related articles for article (PubMed ID: 26226608)

  • 1. Nonmuscle Myosin Heavy Chain IIA Mutation Predicts Severity and Progression of Sensorineural Hearing Loss in Patients With MYH9-Related Disease.
    Verver EJ; Topsakal V; Kunst HP; Huygen PL; Heller PG; Pujol-Moix N; Savoia A; Benazzo M; Fierro T; Grolman W; Gresele P; Pecci A
    Ear Hear; 2016; 37(1):112-20. PubMed ID: 26226608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYH9-related disease: a novel prognostic model to predict the clinical evolution of the disease based on genotype-phenotype correlations.
    Pecci A; Klersy C; Gresele P; Lee KJ; De Rocco D; Bozzi V; Russo G; Heller PG; Loffredo G; Ballmaier M; Fabris F; Beggiato E; Kahr WH; Pujol-Moix N; Platokouki H; Van Geet C; Noris P; Yerram P; Hermans C; Gerber B; Economou M; De Groot M; Zieger B; De Candia E; Fraticelli V; Kersseboom R; Piccoli GB; Zimmermann S; Fierro T; Glembotsky AC; Vianello F; Zaninetti C; Nicchia E; Güthner C; Baronci C; Seri M; Knight PJ; Balduini CL; Savoia A
    Hum Mutat; 2014 Feb; 35(2):236-47. PubMed ID: 24186861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease.
    Pecci A; Panza E; Pujol-Moix N; Klersy C; Di Bari F; Bozzi V; Gresele P; Lethagen S; Fabris F; Dufour C; Granata A; Doubek M; Pecoraro C; Koivisto PA; Heller PG; Iolascon A; Alvisi P; Schwabe D; De Candia E; Rocca B; Russo U; Ramenghi U; Noris P; Seri M; Balduini CL; Savoia A
    Hum Mutat; 2008 Mar; 29(3):409-17. PubMed ID: 18059020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYH9-Related Thrombocytopenia: Four Novel Variants Affecting the Tail Domain of the Non-Muscle Myosin Heavy Chain IIA Associated with a Mild Clinical Evolution of the Disorder.
    Zaninetti C; De Rocco D; Giangregorio T; Bozzi V; Demeter J; Leoni P; Noris P; Ryhänen S; Barozzi S; Pecci A; Savoia A
    Hamostaseologie; 2019 Feb; 39(1):87-94. PubMed ID: 29996171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical, pathological, and genetic analysis of ten patients with MYH9-related disease.
    Sun XH; Wang ZY; Yang HY; Cao LJ; Su J; Yu ZQ; Bai X; Ruan CG
    Acta Haematol; 2013; 129(2):106-13. PubMed ID: 23207509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late onset and high-frequency dominant hearing loss in a family with MYH9 disorder.
    Wasano K; Matsunaga T; Ogawa K; Kunishima S
    Eur Arch Otorhinolaryngol; 2016 Nov; 273(11):3547-3552. PubMed ID: 26942920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients with Epstein-Fechtner syndromes owing to MYH9 R702 mutations develop progressive proteinuric renal disease.
    Sekine T; Konno M; Sasaki S; Moritani S; Miura T; Wong WS; Nishio H; Nishiguchi T; Ohuchi MY; Tsuchiya S; Matsuyama T; Kanegane H; Ida K; Miura K; Harita Y; Hattori M; Horita S; Igarashi T; Saito H; Kunishima S
    Kidney Int; 2010 Jul; 78(2):207-14. PubMed ID: 20200500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. R705H mutation of MYH9 is associated with MYH9-related disease and not only with non-syndromic deafness DFNA17.
    Verver E; Pecci A; De Rocco D; Ryhänen S; Barozzi S; Kunst H; Topsakal V; Savoia A
    Clin Genet; 2015 Jul; 88(1):85-9. PubMed ID: 24890873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal manifestations of patients with MYH9-related disorders.
    Han KH; Lee H; Kang HG; Moon KC; Lee JH; Park YS; Ha IS; Ahn HS; Choi Y; Cheong HI
    Pediatr Nephrol; 2011 Apr; 26(4):549-55. PubMed ID: 21210153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes.
    Heath KE; Campos-Barros A; Toren A; Rozenfeld-Granot G; Carlsson LE; Savige J; Denison JC; Gregory MC; White JG; Barker DF; Greinacher A; Epstein CJ; Glucksman MJ; Martignetti JA
    Am J Hum Genet; 2001 Nov; 69(5):1033-45. PubMed ID: 11590545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Gene analysis and clinical features of MYH9-related disease].
    Luo XJ; Cao K; Liu J; Duan QY; Chen SY; Zhang Y; Huang T; Mao XN; Li CG; Chen YS
    Zhonghua Er Ke Za Zhi; 2021 Nov; 59(11):957-962. PubMed ID: 34711031
    [No Abstract]   [Full Text] [Related]  

  • 12. Genotype-phenotype Correlation of the p.R1165C Mutation in the MYH9 Disorder: Report of a Japanese Pedigree.
    Okano S; Takase M; Iseki K; Toriumi N; Kaneda M; Kunishima S
    J Pediatr Hematol Oncol; 2015 Aug; 37(6):e352-5. PubMed ID: 26056797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of Sensorineural Hearing Loss in Patients With MYH9-Related Disease: A Systematic Review.
    Peddu D; Amin S; Ying YM
    Otol Neurotol; 2022 Mar; 43(3):e298-e308. PubMed ID: 35147601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations responsible for MYH9-related thrombocytopenia impair SDF-1-driven migration of megakaryoblastic cells.
    Pecci A; Bozzi V; Panza E; Barozzi S; Gruppi C; Seri M; Balduini CL
    Thromb Haemost; 2011 Oct; 106(4):693-704. PubMed ID: 21833445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haematological characteristics of MYH9 disorders due to MYH9 R702 mutations.
    Kunishima S; Yoshinari M; Nishio H; Ida K; Miura T; Matsushita T; Hamaguchi M; Saito H
    Eur J Haematol; 2007 Mar; 78(3):220-6. PubMed ID: 17241369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYH9-related disease: five novel mutations expanding the spectrum of causative mutations and confirming genotype/phenotype correlations.
    De Rocco D; Zieger B; Platokouki H; Heller PG; Pastore A; Bottega R; Noris P; Barozzi S; Glembotsky AC; Pergantou H; Balduini CL; Savoia A; Pecci A
    Eur J Med Genet; 2013 Jan; 56(1):7-12. PubMed ID: 23123319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes.
    Arrondel C; Vodovar N; Knebelmann B; Grünfeld JP; Gubler MC; Antignac C; Heidet L
    J Am Soc Nephrol; 2002 Jan; 13(1):65-74. PubMed ID: 11752022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-muscle myosin heavy chain IIA and IIB interact and co-localize in living cells: relevance for MYH9-related disease.
    Marini M; Bruschi M; Pecci A; Romagnoli R; Musante L; Candiano G; Ghiggeri GM; Balduini C; Seri M; Ravazzolo R
    Int J Mol Med; 2006 May; 17(5):729-36. PubMed ID: 16596254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and treatment of
    Rabbolini DJ; Chun Y; Latimer M; Kunishima S; Fixter K; Valecha B; Tan P; Chew LP; Kile BT; Burt R; Radhakrishnan K; Bird R; Ockelford P; Gabrielli S; Chen Q; Stevenson WS; Ward CM; Morel-Kopp MC
    Platelets; 2018 Dec; 29(8):793-800. PubMed ID: 29090586
    [No Abstract]   [Full Text] [Related]  

  • 20. MYH9-related disorders: report on a patient of Greek origin presenting with macroscopic hematuria and presenile cataract, caused by an R1165C mutation.
    Economou M; Batzios SP; Pecci A; Printza N; Savoia A; Barozzi S; Theodoridou S; Teli A; Psillas G; Zafeiriou DI
    J Pediatr Hematol Oncol; 2012 Aug; 34(6):412-5. PubMed ID: 22627578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.